NASDAQ · VIGL
Healthcare · Biotechnology
$8.05
Up+$0.00 (+0.00%)
Updated Aug 16, 2026, 3:12 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
VIGL does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning VIGL.
VIGL research
Company profile and research snapshot.
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 28, 2025 | Stifel | Hold | — |
| May 27, 2025 | HC Wainwright & Co. | Neutral | — |
| May 22, 2025 | JMP Securities | Market Perform | — |
| May 22, 2025 | William Blair | Market Perform | — |
| May 22, 2025 | Wedbush | Neutral | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Aug 6, 2025
Sanofi has completed its acquisition of Vigil Neuroscience for $470 million, gaining a novel TREM2 agonist (VG-3927) for potential Alzheimer's disease treatment and strengthening its neurology research pipeline.
GlobeNewswire Inc. · Aug 6, 2025
Sanofi has completed the acquisition of Vigil Neuroscience for approximately $470 million, gaining rights to VG-3927, a potential Alzheimer's treatment, and expanding its neurodegenerative disease research pipeline.
GlobeNewswire Inc. · Jul 3, 2025
Law firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches for several companies involving mergers and acquisitions.
GlobeNewswire Inc. · Jun 13, 2025
Brodsky & Smith is investigating potential breaches of fiduciary duties by the boards of Crown Electrokinetics, Elevation Oncology, Sitio Royalties, and Vigil Neuroscience in relation to proposed acquisitions.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning VIGL.
No results
No recent SID articles mention VIGL.
